| Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study CJ Langer, SM Gadgeel, H Borghaei, VA Papadimitrakopoulou, A Patnaik, ... The lancet oncology 17 (11), 1497-1508, 2016 | 1522 | 2016 |
| Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology DS Ettinger, DE Wood, DL Aisner, W Akerley, J Bauman, LR Chirieac, ... Journal of the National Comprehensive Cancer Network 15 (4), 504-535, 2017 | 1245 | 2017 |
| NCCN guidelines insights: non–small cell lung cancer, version 1.2020: featured updates to the NCCN guidelines DS Ettinger, DE Wood, C Aggarwal, DL Aisner, W Akerley, JR Bauman, ... Journal of the National Comprehensive Cancer Network 17 (12), 1464-1472, 2019 | 1185* | 2019 |
| Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology DS Ettinger, DE Wood, DL Aisner, W Akerley, JR Bauman, A Bharat, ... Journal of the National Comprehensive Cancer Network 20 (5), 497-530, 2022 | 1027 | 2022 |
| NCCN guidelines insights: non–small cell lung cancer, version 2.2021: featured updates to the NCCN guidelines DS Ettinger, DE Wood, DL Aisner, W Akerley, JR Bauman, A Bharat, ... Journal of the National Comprehensive Cancer Network 19 (3), 254-266, 2021 | 923 | 2021 |
| Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study COVIDSurg Collaborative Anaesthesia 76 (6), 748-758, 2021 | 589* | 2021 |
| NCCN guidelines insights: non–small cell lung cancer, version 5.2018 DS Ettinger, DL Aisner, DE Wood, W Akerley, J Bauman, JY Chang, ... Journal of the National Comprehensive Cancer Network 16 (7), 807-821, 2018 | 534 | 2018 |
| Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials M Khunger, S Rakshit, V Pasupuleti, AV Hernandez, P Mazzone, ... Chest 152 (2), 271-281, 2017 | 457 | 2017 |
| Mechanisms of hypertension associated with BAY 43-9006 ML Veronese, A Mosenkis, KT Flaherty, M Gallagher, JP Stevenson, ... Journal of clinical oncology 24 (9), 1363-1369, 2006 | 429 | 2006 |
| Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow JP Stevenson, M Rosen, W Sun, M Gallagher, DG Haller, D Vaughn, ... Journal of Clinical Oncology 21 (23), 4428-4438, 2003 | 352 | 2003 |
| Clinical pharmacokinetics and administration of established platinum drugs PJ O'Dwyer, JP Stevenson, SW Johnson Drugs 59, 19-27, 2000 | 309 | 2000 |
| NCCN guidelines® Insights: non–small cell lung cancer, version 2.2023: featured updates to the NCCN guidelines DS Ettinger, DE Wood, DL Aisner, W Akerley, JR Bauman, A Bharat, ... Journal of the National Comprehensive Cancer Network 21 (4), 340-350, 2023 | 282 | 2023 |
| Elective cancer surgery in COVID-19–free surgical pathways during the SARS-CoV-2 pandemic: an international, multicenter, comparative cohort study JC Glasbey, D Nepogodiev, JFF Simoes, O Omar, E Li, ML Venn, PGDME, ... Journal of Clinical Oncology 39 (1), 66-78, 2021 | 281 | 2021 |
| Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study J Glasbey, A Ademuyiwa, A Adisa, E AlAmeer, AP Arnaud, F Ayasra, ... The Lancet Oncology 22 (11), 1507-1517, 2021 | 274 | 2021 |
| Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma HL Kindler, TG Karrison, DR Gandara, C Lu, LM Krug, JP Stevenson, ... Journal of clinical oncology 30 (20), 2509-2515, 2012 | 251 | 2012 |
| Prescribing in palliative care as death approaches DC Currow, JP Stevenson, AP Abernethy, J Plummer, TM Shelby‐James Journal of the American Geriatrics Society 55 (4), 590-595, 2007 | 247 | 2007 |
| 24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed and carboplatin with or without Pembrolizumab as first-line therapy for advanced nonsquamous non–small cell lung … H Borghaei, CJ Langer, S Gadgeel, VA Papadimitrakopoulou, A Patnaik, ... Journal of Thoracic Oncology 14 (1), 124-129, 2019 | 221 | 2019 |
| Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non–small-cell lung carcinoma TJ Robnett, M Machtay, JP Stevenson, KM Algazy, SM Hahn Journal of clinical oncology 19 (5), 1344-1349, 2001 | 214 | 2001 |
| Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC) SM Gadgeel, NA Pennell, MJ Fidler, B Halmos, P Bonomi, J Stevenson, ... Journal of Thoracic Oncology 13 (9), 1393-1399, 2018 | 201 | 2018 |
| Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells D Roberts, J Schick, S Conway, S Biade, PB Laub, JP Stevenson, ... British journal of cancer 92 (6), 1149-1158, 2005 | 196 | 2005 |
